MRTX9768 hydrochloride

• CAT Number: I044579
• Molecular Formula: C24H18ClFN6O
• Molecular Weight: 460.89
• Purity: ≥95%
• Synonyms: 2-[4-[4-(aminomethyl)-1-oxo-2H-phthalazin-6-yl]-2-methylpyrazol-3-yl]-3-fluoronaphthalene-1-carbonitrile;hydrochloride
• IUPAC Name: 2-[4-[4-(aminomethyl)-1-oxo-2H-phthalazin-6-yl]-2-methylpyrazol-3-yl]-3-fluoronaphthalene-1-carbonitrile
• InChI: InChI=1S/C24H17FN6O/c1-31-23(22-18(10-26)15-5-3-2-4-13(15)9-20(22)25)19(12-28-31)14-6-7-16-17(8-14)21(11-27)29-30-24(16)32/h2-9,12H,11,27H2,1H3,(H,30,32)
• InChIKey: BPTYWAYMKBEXES-UHFFFAOYSA-N
• SMILES: CN1C(=C(C=N1)C2=CC3=C(C=C2)C(=O)NN=C3CN)C4=C(C5=CC=CC=C5C=C4F)C#N

MRTX9768 hydrochloride（Cat No.:I044579）is a selective, covalent inhibitor of PRMT5 (protein arginine methyltransferase 5), designed to target PRMT5–MTA complexes commonly found in MTAP-deleted cancers. By irreversibly binding to the PRMT5 active site, MRTX9768 hydrochloride suppresses symmetric arginine dimethylation, disrupting oncogenic gene expression and promoting cancer cell death. It exhibits strong antitumor activity in preclinical models with favorable pharmacokinetics and selectivity. This compound is under investigation for treating MTAP-deleted tumors, including certain gliomas and non-small cell lung cancers. MRTX9768 hydrochloride is a promising candidate for targeted epigenetic cancer therapy.